Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F18%3A00104534" target="_blank" >RIV/00216224:14110/18:00104534 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience

Original language description

Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience, Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

10606 - Microbiology

Project

<a href="/en/project/NV16-32743A" target="_blank" >NV16-32743A: Predictive stratification of CLL patients for therapy involving monoclonal antibodies targeting CD20 antigen</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů